NAGE trades 206.1% below Wall Street's consensus target of $10.50.
Last 12 months price action with 12-month analyst target path
The base valuation assumes NAGE achieves its forward estimates and maintains a stable P/E multiple of 15.0x. This scenario reflects the blended consensus of 5 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 6, 2026, Niagen Bioscience Inc (NAGE) has a Wall Street consensus price target of $10.50, based on estimates from 5 covering analysts. With the stock currently trading at $3.43, this represents a potential upside of +206.1%. The company has a market capitalization of $273M.
Analyst price targets range from a low of $10.00 to a high of $11.00, representing a 10% spread in expectations. The median target of $10.50 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 5 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, NAGE trades at a trailing P/E of 17.1x and forward P/E of 15.0x. Analysts expect EPS to grow +4.0% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $2.90, with bear and bull scenarios of $1.82 and $3.82 respectively. Model confidence stands at 65/100, reflecting moderate uncertainty in projections.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
NRXPNRx Pharmaceuticals, Inc. | $67M | $3.87 | — | — | — | — | — |
HALOHalozyme Therapeutics, Inc. | $9.4B | $79.45 | $88.25 | +11.1% | Buy | 9.8x | 27 |
NBIXNeurocrine Biosciences, Inc. | $17.5B | $174.26 | $188.62 | +8.2% | Buy | 22.6x | 37 |
NTLAIntellia Therapeutics, Inc. | $2.0B | $17.56 | $26.13 | +48.8% | Buy | — | 39 |
BEAMBeam Therapeutics Inc. | $3.6B | $34.79 | $48.00 | +38.0% | Buy | — | 27 |
EDITEditas Medicine, Inc. | $357M | $3.65 | $5.00 | +37.0% | Buy | — | 25 |
CRSPCRISPR Therapeutics AG | $5.8B | $60.08 | $71.67 | +19.3% | Buy | — | 38 |
AMGNAmgen Inc. | $201.9B | $374.15 | $352.50 | -5.8% | Buy | 16.7x | 38 |
PFEPfizer Inc. | $138.3B | $24.32 | $26.75 | +10.0% | Hold | 8.2x | 39 |
MRKMerck & Co., Inc. | $319.9B | $129.52 | $133.77 | +3.3% | Buy | 25.2x | 37 |
Quick answers to the most common questions about buying NAGE stock.
The consensus Wall Street price target for NAGE is $10.5, representing 206.1% upside from the current price of $3.43. With 5 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
NAGE has a consensus rating of "Buy" based on 5 Wall Street analysts. The rating breakdown is predominantly bullish, with 5 Buy/Strong Buy ratings. The consensus 12-month price target of $10.5 implies 206.1% upside from current levels.
With a forward P/E of 14.9651x, NAGE trades at a relatively low valuation. The consensus target of $10.5 implies 206.1% appreciation, suggesting meaningful undervaluation.
The most bullish Wall Street analyst has a price target of $11 for NAGE, while the most conservative target is $10. The consensus of $10.5 represents the median expectation. Our quantitative valuation model projects a bull case target of $4 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
NAGE is moderately covered, with 5 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 5 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month NAGE stock forecast based on 5 Wall Street analysts shows a consensus price target of $10.5, with estimates ranging from $10 (bear case) to $11 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $3, with bear/bull scenarios of $2/$4.
Our quantitative valuation model calculates NAGE's fair value at $3 (base case), with a bear case of $2 and bull case of $4. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 65/100.
NAGE trades at a forward P/E ratio of 15.0x based on next-twelve-months earnings estimates compared to a trailing P/E of 17.1x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on NAGE, with a "Buy" consensus rating and $10.5 price target (206.1% upside). 5 of 5 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
NAGE analyst price targets range from $10 to $11, a 10% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $10.5 consensus represents the middle ground. Our model's $2-$4 range provides an independent fundamental perspective.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.